ANI Pharmaceuticals Inc (ANIP) has a current Price-to-Book (P/B) ratio of 3.24. Compared to its 3-year average P/B ratio of 2.85, the current P/B ratio is approximately 13.84% higher. Relative to its 5-year average P/B ratio of 2.49, the current P/B ratio is about 30.38% higher. ANI Pharmaceuticals Inc (ANIP) has a Forward Free Cash Flow (FCF) yield of approximately 9.50%. Compared to its 3-year average FCF yield of 5.90%, the current FCF yield is approximately 60.96% lower. Relative to its 5-year average FCF yield of 2.49%, the current FCF yield is about 280.84% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ANIP competitors is 6.13, providing a benchmark for relative valuation. ANI Pharmaceuticals Inc Corp (ANIP.O) exhibits a P/S ratio of 1.79, which is -70.71% above the industry average. Given its robust revenue growth of 29.64%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ANIP increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ANIP in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ANIP currently overvalued or undervalued?

What is ANI Pharmaceuticals Inc (ANIP) fair value?

ANIP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of ANI Pharmaceuticals Inc (ANIP) is between 71.42 to 120.25 according to relative valuation method.

How does ANIP's valuation metrics compare to the industry average?

The average P/S ratio for ANIP's competitors is 6.13, providing a benchmark for relative valuation. ANI Pharmaceuticals Inc Corp (ANIP) exhibits a P/S ratio of 1.79, which is -70.71% above the industry average. Given its robust revenue growth of 29.64%, this premium appears sustainable.

What is the current P/B ratio for ANI Pharmaceuticals Inc (ANIP) as of Mar 03 2026?

As of Mar 03 2026, ANI Pharmaceuticals Inc (ANIP) has a P/B ratio of 3.24. This indicates that the market values ANIP at 3.24 times its book value.

What is the current FCF Yield for ANI Pharmaceuticals Inc (ANIP) as of Mar 03 2026?

As of Mar 03 2026, ANI Pharmaceuticals Inc (ANIP) has a FCF Yield of 9.50%. This means that for every dollar of ANI Pharmaceuticals Inc's market capitalization, the company generates 9.50 cents in free cash flow.

What is the current Forward P/E ratio for ANI Pharmaceuticals Inc (ANIP) as of Mar 03 2026?

As of Mar 03 2026, ANI Pharmaceuticals Inc (ANIP) has a Forward P/E ratio of 9.96. This means the market is willing to pay $9.96 for every dollar of ANI Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for ANI Pharmaceuticals Inc (ANIP) as of Mar 03 2026?

As of Mar 03 2026, ANI Pharmaceuticals Inc (ANIP) has a Forward P/S ratio of 1.79. This means the market is valuing ANIP at $1.79 for every dollar of expected revenue over the next 12 months.

ANIP Valuation